Cleveland Clinic cancer researchers are involved with more than 50 studies that will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, June 3—7, 2022.
Key research from Cleveland Clinic focuses on advancements in the prevention and risk reduction in melanoma; care delivery and treatment in myelofibrosis, metastatic urothelial cancer and prostate cancer; and disparities in research funding and screenings. Some research highlights our experts can discuss are listed below. They can also provide outside perspective on other ASCO presentations.
Germline predisposition in oncologic and dermatologic melanoma cohorts.
Defining “platinum-ineligible” patients with metastatic urothelial cancer (mUC).
Breast cancer screening in persons experiencing homelessness.
Next-generation sequencing (NGS): How often is testing performed too late?